Carlsmed Statistics
Total Valuation
Carlsmed has a market cap or net worth of $374.87 million. The enterprise value is $307.56 million.
| Market Cap | 374.87M |
| Enterprise Value | 307.56M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Carlsmed has 27.30 million shares outstanding. The number of shares has increased by 496.29% in one year.
| Current Share Class | 27.30M |
| Shares Outstanding | 27.30M |
| Shares Change (YoY) | +496.29% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 12.13% |
| Owned by Institutions (%) | 25.60% |
| Float | 14.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.84 |
| Forward PS | 4.00 |
| PB Ratio | 4.44 |
| P/TBV Ratio | 4.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.84, with a Debt / Equity ratio of 0.26.
| Current Ratio | 8.84 |
| Quick Ratio | 8.31 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.98 |
Financial Efficiency
Return on equity (ROE) is -66.14% and return on invested capital (ROIC) is -32.32%.
| Return on Equity (ROE) | -66.14% |
| Return on Assets (ROA) | -28.19% |
| Return on Invested Capital (ROIC) | -32.32% |
| Return on Capital Employed (ROCE) | -36.54% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $498,386 |
| Profits Per Employee | -$286,181 |
| Employee Count | 127 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 8.85 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +5.13% |
| 50-Day Moving Average | 11.70 |
| 200-Day Moving Average | 11.88 |
| Relative Strength Index (RSI) | 66.17 |
| Average Volume (20 Days) | 122,851 |
Short Selling Information
The latest short interest is 1.36 million, so 4.97% of the outstanding shares have been sold short.
| Short Interest | 1.36M |
| Short Previous Month | 1.31M |
| Short % of Shares Out | 4.97% |
| Short % of Float | 9.16% |
| Short Ratio (days to cover) | 7.57 |
Income Statement
In the last 12 months, Carlsmed had revenue of $63.30 million and -$36.35 million in losses. Loss per share was -$1.43.
| Revenue | 63.30M |
| Gross Profit | 48.50M |
| Operating Income | -38.67M |
| Pretax Income | -36.35M |
| Net Income | -36.35M |
| EBITDA | -38.26M |
| EBIT | -38.67M |
| Loss Per Share | -$1.43 |
Balance Sheet
The company has $89.22 million in cash and $21.92 million in debt, with a net cash position of $67.31 million or $2.47 per share.
| Cash & Cash Equivalents | 89.22M |
| Total Debt | 21.92M |
| Net Cash | 67.31M |
| Net Cash Per Share | $2.47 |
| Equity (Book Value) | 84.25M |
| Book Value Per Share | 3.09 |
| Working Capital | 97.20M |
Cash Flow
In the last 12 months, operating cash flow was -$34.15 million and capital expenditures -$432,000, giving a free cash flow of -$34.58 million.
| Operating Cash Flow | -34.15M |
| Capital Expenditures | -432,000 |
| Depreciation & Amortization | 409,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -34.58M |
| FCF Per Share | -$1.27 |
Margins
Gross margin is 76.63%, with operating and profit margins of -61.09% and -57.42%.
| Gross Margin | 76.63% |
| Operating Margin | -61.09% |
| Pretax Margin | -57.42% |
| Profit Margin | -57.42% |
| EBITDA Margin | -60.44% |
| EBIT Margin | -61.09% |
| FCF Margin | n/a |
Dividends & Yields
Carlsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -496.29% |
| Shareholder Yield | -496.29% |
| Earnings Yield | -9.83% |
| FCF Yield | -9.35% |
Analyst Forecast
The average price target for Carlsmed is $19.20, which is 39.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.20 |
| Price Target Difference | 39.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 43.78% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Carlsmed has an Altman Z-Score of 4.84 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.84 |
| Piotroski F-Score | 4 |